Navigation Links
AAO-HNS releases consensus statement: diagnosis and management of nasal valve compromise
Date:7/1/2010

Alexandria, VA Today, the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNS) announced the release of a consensus statement to address ambiguities and disparities in the diagnosis and management of nasal valve compromise (NVC).

Nasal valve compromise (NVC) is a distinct and primary cause for symptomatic nasal airway obstruction, yet there remain ambiguities and disparities in the diagnosis and management of this condition. Other etiologies for nasal airway obstruction, either structural or inflammatory, may co-exist or mimic the symptoms caused by NVC. Furthermore, current procedural terminology (CPT) billing coding schemes for nasal valve surgery are unclear, as are the boundaries and overlap with other nasal surgical codes.

In order to help organize and disseminate information regarding NVC, the AAO-HNS convened a panel of member experts to create the clinical consensus statement (CCS) which is designed to inform and educate clinicians. Clinical consensus statements are provided for informational and educational purposes only. They are based on the opinions of carefully chosen expert panels and are promoted as such. The purpose of the expert panel is to synthesize information, along with possible conflicting interpretations of the data, into clear and accurate answers to the question of interest. The primary objective of the panel's work was to develop a CCS on NVC using a Modified Delphi Method, which is a rigorous and standardized approach to minimize bias and facilitate an established position.

The panel found consistent literature of benefit of surgical treatment of NVC, but the evidence relied mostly on uncontrolled studies. The panel generally agreed on the anatomic and functional features that define the distinct clinical entity of NVC and that it is best evaluated with history and physical exam findings. Endoscopy and photography are useful but not always routinely indicated, while radiographic studies are not felt to be useful in evaluating NVC. Other objective nasal outcome measures are not routinely used and may not be useful for this particular nasal condition. Nasal steroid medication is not useful for treating NVC in the absence of rhinitis, and mechanical treatments may be useful in selected patients. Surgical treatment is the primary mode of treatment of NVC, but bill coding remains ambiguous and confusing.


'/>"/>

Contact: Mary Stewart
newsroom@entnet.org
703-535-3762
American Academy of Otolaryngology -- Head and Neck Surgery
Source:Eurekalert

Related medicine news :

1. Apps For All Releases New iPhone/iPad Trend Setting App – Mood Lifters
2. DrFinders Releases Searchable Online Directory of Doctors for All Medical Needs
3. Aerohive Networks Releases New Version of Free Wi-Fi Planning Tool
4. Mercy Ships Releases Abel Dalome Just in Time for Father's Day - A Father's Dream Becomes a Reality
5. Progressive Medical Releases 2010 Workers' Compensation Drug Spend Analysis
6. Intellidimension Releases New Version of Semantic Web Technologies
7. Hosting Metro Releases New Website and Upgraded Pricing Plans For All Web Hosting Packages
8. ageet Corporation Releases GuardVox Phone to Protect IP Calls
9. VoIP Supply Releases VoIP Phone Buyers Guide
10. Albeo Releases Six New Surface Mount LED Lighting Fixtures
11. Purity Products Releases Ultimate Sleep Plus Melatonin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... NY (PRWEB) , ... December 05, 2016 , ... ... to use a patent-pending blend of L-Citrulline and glutathione to enhance production of ... a combination that studies have shown to produce NO twice as effectively and ...
(Date:12/5/2016)... ... December 05, 2016 , ... Eating disorders ... goal of Castlewood Treatment Centers has always been to promote the power of ... people as possible. In that spirit, Castlewood has announced two new hires, both ...
(Date:12/5/2016)... ... December 05, 2016 , ... U.S. Apple Association (USApple) ... part of the second annual Apples for Education: Buy an Apple, Help a ... providing healthy food for students to take home to their families; solar technology to ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Partners ("GPP") portfolio company, today announced it has acquired the assets of ... was previously a subsidiary of Chiltern International and focuses on clinical trial ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)...  CVS Health, the nation,s largest pharmacy innovation company, ... of 100 percent on the Corporate Equality Index (CEI) ... annual national benchmarking survey and report on corporate policies ... Human Rights Campaign Foundation. "Our company,s ... customers and suppliers bring to CVS Health," said ...
Breaking Medicine Technology: